[go: up one dir, main page]

AR038571A1 - Procedimiento para la preparacion de un producto de inhalacion en polvo que contiene una sal del antagonista de cgrp, bibn4096 - Google Patents

Procedimiento para la preparacion de un producto de inhalacion en polvo que contiene una sal del antagonista de cgrp, bibn4096

Info

Publication number
AR038571A1
AR038571A1 ARP030100536A ARP030100536A AR038571A1 AR 038571 A1 AR038571 A1 AR 038571A1 AR P030100536 A ARP030100536 A AR P030100536A AR P030100536 A ARP030100536 A AR P030100536A AR 038571 A1 AR038571 A1 AR 038571A1
Authority
AR
Argentina
Prior art keywords
bibn4096
preparation
powder inhalation
salt
procedure
Prior art date
Application number
ARP030100536A
Other languages
English (en)
Inventor
Trunk Michael Dr
Claudius Weiler
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of AR038571A1 publication Critical patent/AR038571A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Preparación, procedimiento para la preparación de un producto de inhalación en polvo para el tratamiento de la migrana que contiene una sal del principio BIBN4096, así como a los productos de inhalación en polvo obtenibles mediante el procedimiento. Reivindicación 1: Sales por adición de ácidos de la base de principio activo 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihidro-2(1H)-oxoquina-zolin-3-il)-1-piperidinil]carbonil]-D-tirosil]-L-lisil]-4-(4-piridinil)-piperazina [BIBN4096] de la fórmula (1).
ARP030100536A 2002-02-19 2003-02-19 Procedimiento para la preparacion de un producto de inhalacion en polvo que contiene una sal del antagonista de cgrp, bibn4096 AR038571A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10206770A DE10206770A1 (de) 2002-02-19 2002-02-19 Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096

Publications (1)

Publication Number Publication Date
AR038571A1 true AR038571A1 (es) 2005-01-19

Family

ID=27635111

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100536A AR038571A1 (es) 2002-02-19 2003-02-19 Procedimiento para la preparacion de un producto de inhalacion en polvo que contiene una sal del antagonista de cgrp, bibn4096

Country Status (12)

Country Link
EP (1) EP1478382B1 (es)
JP (1) JP4085064B2 (es)
AR (1) AR038571A1 (es)
AT (1) ATE347900T1 (es)
AU (1) AU2003208853A1 (es)
CA (1) CA2476711A1 (es)
DE (2) DE10206770A1 (es)
ES (1) ES2279094T3 (es)
PE (1) PE20030931A1 (es)
TW (1) TW200400184A (es)
UY (1) UY27673A1 (es)
WO (1) WO2003070753A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
DE10314617A1 (de) * 2003-04-01 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung des Hydrochlorids der Wirkstoffbase 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin in Kombination mit Sumatriptan zur Behandlung von Migräne
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
DE10338407A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
DE10338399A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
DE10338402A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
US7569578B2 (en) 2003-12-05 2009-08-04 Bristol-Meyers Squibb Company Heterocyclic anti-migraine agents
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
DE102004018795A1 (de) * 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7384931B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
US7439237B2 (en) 2005-04-15 2008-10-21 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0927192T3 (da) * 1996-09-10 2004-09-13 Boehringer Ingelheim Pharma Modificerede aminosyrer, lægemidler indeholdende disse forbindelser og fremgangsmåder til deres fremstilling
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US6509005B1 (en) * 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
DE19937304C2 (de) * 1999-08-10 2003-08-21 Boehringer Ingelheim Pharma Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
IL149085A0 (en) * 1999-10-29 2002-11-10 Inhale Therapeutic Syst A dry powder composition containing a di or tripeptide

Also Published As

Publication number Publication date
ATE347900T1 (de) 2007-01-15
ES2279094T3 (es) 2007-08-16
UY27673A1 (es) 2003-09-30
DE10206770A1 (de) 2003-08-28
AU2003208853A1 (en) 2003-09-09
EP1478382B1 (de) 2006-12-13
TW200400184A (en) 2004-01-01
CA2476711A1 (en) 2003-08-28
PE20030931A1 (es) 2003-12-18
DE50305954D1 (de) 2007-01-25
JP2005538934A (ja) 2005-12-22
EP1478382A1 (de) 2004-11-24
JP4085064B2 (ja) 2008-04-30
WO2003070753A1 (de) 2003-08-28

Similar Documents

Publication Publication Date Title
AR038571A1 (es) Procedimiento para la preparacion de un producto de inhalacion en polvo que contiene una sal del antagonista de cgrp, bibn4096
TW200637828A (en) Novel cis-imidazolines
AR051965A1 (es) Sales de la n-[2-( { (3r)-1-[trans-4-hidroxi-4-(6- metoxipiridin-3-il)-ciclohexil] pirrolidin-3- il} amino)-2- oxoetil]-3-(trifluormetil) benzamida
WO2002055496A8 (en) Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
ECSP066493A (es) Combinaciones sinérgicas de productos activos, fungicidas
JO2371B1 (en) 4-phenyl-pyridine derivatives
EA201070588A1 (ru) Производные 1,2,3-триазола для применения в качестве ингибиторов стеароил-соа десатуразы
PE20070839A1 (es) Derivados de indolobenzazepina como inhibidores de ns5b de vhc
AR079208A2 (es) Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
ATE485269T1 (de) C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
DK1689721T3 (da) Aminopyrazolderivater som GSK-3-ihibitorer
EA200971086A1 (ru) Фармацевтические композиции и способ лечения шизофрении
CO6251249A2 (es) Un medicamento que comprende un derivado un derivado de carbostirilo y donepezilo para tratar enfermedad de alzheimer
CY1111022T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
EA200971087A1 (ru) Фармацевтические композиции и способ лечения острой мании
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
ECSP044979A (es) Uso de bibn4096 en combinación con otros fármacos antimigrañosos para el tratamiento de migraña
DE602006020871D1 (de) Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
SE0002729D0 (sv) Novel compound form
UA92195C2 (ru) Оптически активные карбаматы, способ их получения и их применение в качестве фармацевтических промежуточных соединений
SE0102057D0 (sv) New Salts I
BRPI0517734A (pt) derivados de 1-[(6,7-alcoxiquinoxalinil substituìdo) aminocarbonil]-4- (hetero) arilpiperazina

Legal Events

Date Code Title Description
FB Suspension of granting procedure